Trials / Conditions / Lung Neoplasm Malignant

Lung Neoplasm Malignant

21 registered clinical trials studyying Lung Neoplasm Malignant — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) NCT07286149	Merck Sharp & Dohme LLC	Phase 1 / Phase 2
Recruiting	Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tu NCT07071103	Chuangzhen Chen	Phase 2
Recruiting	Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475- NCT06788912	Merck Sharp & Dohme LLC	Phase 2
Not Yet Recruiting	Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules NCT06530667	Shanghai Zhongshan Hospital	N/A
Recruiting	Benefit of Spectral Information in Patients Suspected for Lung Cancer NCT06440616	Copenhagen University Hospital at Herlev	N/A
Recruiting	Confocal Laser Endomicroscopy VERification NCT06079970	Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)	N/A
Recruiting	MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell L NCT05974475	European Institute of Oncology	—
Completed	Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer NCT05890872	Galvanize Therapeutics, Inc.	N/A
Recruiting	Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer NCT04973293	Ruijin Hospital	N/A
Completed	Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years NCT05404022	University of Hull	N/A
Unknown	Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy NCT05414188	Asan Medical Center	N/A
Terminated	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873	Blueprint Medicines Corporation	Phase 1
Terminated	Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Soli NCT05013554	Sanofi	Phase 1
Unknown	Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy NCT04778826	Otto Wagner Hospital	N/A
Completed	Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] NCT04059887	Chonnam National University Hospital	Phase 4
Completed	Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies NCT03834116	The Hong Kong Polytechnic University	N/A
Suspended	Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis NCT04036721	National Institute for Tuberculosis and Lung Diseases, Poland	Phase 4
Completed	Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer NCT03352245	Yale University	N/A
Completed	Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery NCT03824977	University Hospital, Rouen	—
Unknown	Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC NCT03525782	The First Affiliated Hospital of Guangdong Pharmaceutical University	Phase 1 / Phase 2
Terminated	Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer NCT02985203	Guangdong Association of Clinical Trials	Phase 2